论文部分内容阅读
目的:探讨厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭的临床疗效。方法:通过对2013年1月至2015年2月本院治疗的78例老年重症心力衰竭患者随机分组,其中对照组患者应用美托洛尔治疗,观察组患者实施厄贝沙坦氢氯噻嗪联合美托洛尔治疗。观察比较两组患者治疗效果、左心室射血分数(LVEF)水平和纽约心脏病协会(NYHA)心功能评分及脑钠肽(BNP)水平和血压、心率。结果:观察组患者治疗效果同对照组比较明显提高,观察组患者LVEF水平、NYHA心功能评分、BNP水平、血压和心率同对照组比较均明显改善,差异具有统计学意义(P<0.05)。结论:针对老年重症心力衰竭患者应用厄贝沙坦氢氯噻嗪联合美托洛尔治疗可提高治疗效果,促进心功能恢复,降低血压,改善预后,提高患者生活质量。
Objective: To investigate the clinical efficacy of irbesartan and hydrochlorothiazide combined with metoprolol in the treatment of senile patients with severe heart failure. Methods: From January 2013 to February 2015 in our hospital, 78 cases of elderly patients with severe heart failure were randomly divided into control group, metoprolol treatment group, the observation group patients with irbesartan hydrochlorothiazide combined with the United States care Lol treatment. The therapeutic effect, left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) cardiac function score, BNP level, blood pressure and heart rate were compared between the two groups. Results: The therapeutic effect of the observation group was significantly higher than that of the control group. The LVEF level, NYHA functional score, BNP level, blood pressure and heart rate in the observation group were significantly improved compared with the control group (P <0.05). Conclusion: Irbesartan hydrochlorothiazide combined with metoprolol in elderly patients with severe heart failure can improve the therapeutic effect, promote the recovery of cardiac function, lower blood pressure, improve the prognosis and improve the quality of life of patients.